Maaike R. Scheenstra

Maaike R. Scheenstra

Auto-generated profile, based on publicly available information

Maaike R. Scheenstra

Division of Molecular Host Defence, Dept. of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMaaike R. Scheenstra
Maaike R. Scheenstra
MBMatthias van Den Belt
Matthias van Den Belt
JBJohanna L. M. Tjeerdsma-Van Bokhoven
Johanna L. M. Tjeerdsma-Van Bokhoven
VSViktoria A. F. Schneider
Viktoria A. F. Schneider
SOSoledad R. Ordonez
Soledad R. Ordonez
HHHenk Haagsman
Henk Haagsman
Host defense peptides (HDPs) play a pivotal role in innate immunity and have, in addition to antimicrobial activity, also important immunomodulatory functions. Bacteria are less likely to develop resistance against HDPs because these peptides target and kill bacteria in multiple ways, as well as modulate the immune system. Therefore, HDPs, and derivatives thereof, are promising alternatives to traditional antibiotics. Hardly anything is known about the immunomodulatory functions of porcine cathelicidin PMAP-36. In this study, we aimed to determine both antibacterial and immunomodulatory activities of PMAP-36 comparing the properties of PMAP-36 analogs with two well-studied peptides, human LL-37 and chicken CATH-2. Transmission electron microscopy revealed different killing mechanisms of E. coli for PMAP-36, CATH-2 and LL-37. LL-37 binds LPS very weakly in contrast to PMAP-36, but it inhibits LPS activation of macrophages the strongest. The first 11 amino acids of the N-terminal side of PMAP-36 are dispensable for E. coli killing, LPS-neutralization and binding. Deletion of four additional amino acids resulted in a strong decrease in activity. The activity of full length PMAP-36 was not affected by monomerization, whereas the shorter analogs require dimerization for proper immunomodulatory activity but not for their antibacterial activity.

1 June 2018 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Open access
JGJiye Gao
Jiye Gao
MSMaaike R. Scheenstra
Maaike R. Scheenstra
ADAlbert van Dijk
Albert van Dijk
EVEdwin J.A. Veldhuizen
Edwin J.A. Veldhuizen
HHHenk Haagsman
Henk Haagsman

1 February 2022 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Open access
RHRoel M. van Harten
Roel M. van Harten
EVEdwin Veldhuizen
Edwin Veldhuizen
HHHenk Haagsman
Henk Haagsman
MSMaaike R. Scheenstra
Maaike R. Scheenstra
Infectious diseases in pigs cause monetary loss to farmers and pose a zoonotic risk. Therefore, it is important to obtain more porcine specific immunological knowledge as a measure to protect against infectious diseases, for example by exploring immunomodulators that are usable as vaccine adjuvants. Cathelicidins are a class of host defence peptides (HDPs) able to directly kill microbes as well as exert a diverse range of effects on the immune system. The peptides have shown promise as immunomodulatory peptides in many applications, including vaccines. However, it is currently unknown what the precise effect of these peptides is on porcine immune cells and whether peptides of other species might also have a strong immunomodulatory effect on porcine macrophages. Mononuclear bone marrow cells of pigs, aged 5-6 months, were cultured into M1 or M2 macrophages and stimulated with LPS or whole bacteria in the presence of host defence peptides (HDPs). CATH-2 and LL-37 strongly inhibited LPS-induced activation of M1 macrophages, the inhibition of LPS-induced activation of M2 macrophages by HDPs was milder, showing that the peptides have selective effects on different cell types. Upon stimulation with whole bacteria, only CATH-2 could effectively inhibit macrophage activation, showing the potent anti-inflammatory potential of this peptide. These results show that porcine peptides are not necessarily the most active in a porcine system, and that CATH-2 is effective in a porcine system as an anti-inflammatory immune modulator, which can be used, for example, in inactivated pathogen vaccines.

10 December 2019 in Protein & Peptide Letters
Verified
Journal Article
Open access
MKMarina D. Kraaij
Marina D. Kraaij
ADAlbert Van Dijk
Albert Van Dijk
MSMaaike R. Scheenstra
Maaike R. Scheenstra
RHRoel Van Harten
Roel Van Harten
HHHenk Haagsman
Henk Haagsman
EVEdwin Veldhuizen
Edwin Veldhuizen
Background: Cathelicidins are a family of Host Defense Peptides (HDPs), that play an important role in the innate immune response. They exert both broad-spectrum antimicrobial activity against pathogens, and strong immunomodulatory functions that affect the response of innate and adaptive immune cells. Objective: The aim of this study was to investigate immunomodulation by the chicken cathelicidin CATH-2 and compare its activities to those of the human cathelicidin LL-37. Method: Chicken macrophages and chicken monocytes were incubated with cathelicidins. Activation of immune cells was determined by measuring surface markers Mannose Receptor Ctype 1 (MRC1) and MHC-II. Cytokine production was measured by qPCR and nitric oxide production was determined using the Griess assay. Finally, the effect of cathelicidins on phagocytosis was measured using carboxylate-modified polystyrene latex beads. Results: CATH-2 and its all-D enantiomer D-CATH-2 increased MRC1 and MHC-II expression, markers for antigen presentation, on primary chicken monocytes, whereas LL-37 did not. D-CATH- 2 also increased the MRC1 and MHC-II expression if a chicken macrophage cell line (HD11 cells) was used. In addition, LPS-induced NO production by HD11 cells was inhibited by CATH-2 and D-CATH-2. Conclusion: These results are a clear indication that CATH-2 (and D-CATH-2) affect the activation state of monocytes and macrophages, which leads to optimization of the innate immune response and enhancement of the adaptive immune response.

1 December 2015 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
MSMaaike R. Scheenstra
Maaike R. Scheenstra
VSVishal Salunkhe
Vishal Salunkhe
ICIris Maria De Cuyper
Iris Maria De Cuyper
MHMark Hoogenboezem
Mark Hoogenboezem
ELEveline Li
Eveline Li
LGLaura Gutiérrez
Laura Gutiérrez